Omada Health (NASDAQ:OMDA) CFO Sells $381,332.05 in Stock

Posted by Geri Gentry on Aug 12th, 2026

Omada Health, Inc. (NASDAQ:OMDA – Get Free Report) CFO Steven Cook sold 15,235 shares of the firm’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $25.03, for a total transaction of $381,332.05. Following the sale, the chief financial officer owned 187,209 shares of the company’s stock, valued at $4,685,841.27. The trade was a 7.53% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Omada Health Stock Performance

Shares of NASDAQ OMDA traded down $0.17 during trading on Wednesday, hitting $23.84. The company had a trading volume of 1,552,408 shares, compared to its average volume of 1,274,695. The company has a market cap of $1.46 billion, a P/E ratio of 476.80 and a beta of 1.73. Omada Health, Inc. has a 52 week low of $10.28 and a 52 week high of $26.92. The business’s 50-day moving average is $20.61 and its 200 day moving average is $16.32.

Omada Health (NASDAQ:OMDA – Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The company reported $0.08 earnings per share for the quarter, topping the consensus estimate of ($0.02) by $0.10. The business had revenue of $87.83 million during the quarter, compared to analyst estimates of $80.93 million. Omada Health had a return on equity of 2.67% and a net margin of 1.39%. On average, research analysts expect that Omada Health, Inc. will post -0.01 EPS for the current year.

Key Omada Health News

Here are the key news stories impacting Omada Health this week:

Positive Sentiment: Omada’s second-quarter results provided further evidence that revenue growth is translating into profitability. The company reported earnings of $0.08 per share versus a consensus loss of $0.02 and revenue of approximately $87.8 million, well above the $80.9 million analyst estimate. The results support the bullish case for Omada’s digital chronic-care platform and improving financial execution. Omada Health: Q2 Shows More Evidence Of Growth Converting Into Earnings
Positive Sentiment: Robert W. Baird raised its price target on OMDA from $15 to $25, reflecting improved expectations following the earnings performance. However, the firm maintained a neutral rating, indicating that much of the near-term upside may already be reflected in the stock price. Benzinga analyst update
Neutral Sentiment: Analyst sentiment remains broadly favorable, with a reported consensus rating of “Moderate Buy” and an average price target of $25.67. Recent targets range from $24 to $35, but the wide range highlights uncertainty around valuation and future growth.
Neutral Sentiment: Reported short interest was zero shares, offering no meaningful indication of short-selling pressure or potential short-covering demand.
Negative Sentiment: CEO Sean Duffy disclosed sales of 8,628 shares at an average price of $21.85 and 12,942 shares at $24.81. The transactions reduced his direct ownership by roughly 5% across the reported sales and may weigh on sentiment, although he still owns more than 411,000 shares.
Negative Sentiment: At roughly $24 per share, OMDA trades at a very high price-to-earnings ratio near 480, leaving the stock sensitive to disappointment in growth, margins or future earnings. Its recent performance has already placed it well above its 50-day and 200-day moving averages.

Wall Street Analysts Forecast Growth

OMDA has been the topic of a number of analyst reports. BMO Capital Markets reissued an “outperform” rating and issued a $24.00 price target on shares of Omada Health in a research note on Friday, August 7th. Morgan Stanley reaffirmed an “overweight” rating and set a $30.00 price objective on shares of Omada Health in a research note on Monday, June 22nd. Canaccord Genuity Group raised their target price on shares of Omada Health from $24.00 to $28.00 and gave the stock a “buy” rating in a report on Tuesday, July 21st. Wall Street Zen raised shares of Omada Health from a “hold” rating to a “buy” rating in a research report on Saturday. Finally, Evercore restated an “outperform” rating and set a $20.00 price target on shares of Omada Health in a report on Friday, May 8th. Eleven equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $25.75.

Get Our Latest Report on OMDA

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Raymond James Financial Inc. acquired a new stake in Omada Health during the 2nd quarter worth about $32,000. Quarry LP purchased a new position in Omada Health during the 4th quarter valued at about $29,000. TD Waterhouse Canada Inc. acquired a new position in shares of Omada Health in the 4th quarter valued at about $32,000. Inlight Wealth Management LLC purchased a new stake in shares of Omada Health in the fourth quarter worth approximately $45,000. Finally, Versant Capital Management Inc lifted its position in shares of Omada Health by 319.3% in the second quarter. Versant Capital Management Inc now owns 2,998 shares of the company’s stock worth $66,000 after purchasing an additional 2,283 shares in the last quarter.

Omada Health Company Profile

(Get Free Report)

Omada Health is a digital health company that specializes in the prevention and management of chronic conditions through personalized, technology-driven programs. The company’s platform combines data analytics, behavioral science and human coaching to support individuals at risk for or living with conditions such as prediabetes, type 2 diabetes, hypertension and musculoskeletal disorders. Participants access the program via a mobile app or web portal, where they receive tailored curriculum, feedback on health metrics and ongoing virtual coaching.

In addition to its core disease-management offerings, Omada Health has expanded its services to include mental health support and digital therapeutics for weight management.